会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Safe process for the preparation of balsalazide
    • 安全的制备苦瓜碱的方法
    • US07271253B1
    • 2007-09-18
    • US11501770
    • 2006-08-10
    • Eckardt C. G. WolfNageib MohamedBhaskar Reddy Guntoori
    • Eckardt C. G. WolfNageib MohamedBhaskar Reddy Guntoori
    • C07C245/08C07C245/20
    • C07C245/08C07C245/20
    • A process for the preparation of Balsalazide and its pharmaceutically acceptable salts wherein the reaction comprises: a. the intermediate N-(4-aminobenzoyl)-β-alanine is converted to N-(4-ammoniumbenzoyl)-β-alanine sulfonate salt using a sulfonic acid in water, b. the N-(4-ammoniumbenzoyl)-β-alanine sulfonate salt is treated with aqueous sodium nitrite solution at low temperature to generate N-(4-diazoniumbenzoyl)-β-alanine sulfonate salt, c. the aqueous solution obtained is quenched with aqueous disodium salicylate to furnish Balsalazide disodium solution, d. the solution is acidified to allow isolation of Balsalazide, and e. optionally converting the Balsalazide to a pharmaceutically acceptable salt (such as disodium salt).
    • 一种制备巴拉西平及其可药用盐的方法,其中该反应包括:a。 b)将中间体N-(4-氨基苯甲酰基) - 丙氨酸转化为N-(4-氨基苯甲酰基) - 丙氨酸磺酸盐,使用磺酸在水中。 在低温下用亚硝酸钠水溶液处理N-(4-氨基苯甲酰基) - 丙氨酸磺酸盐,生成N-(4-重氮苯甲酰基) - 丙氨酸磺酸盐,c。 得到的水溶液用水杨酸二钠水溶液淬灭,得到Balsalazide二钠溶液,d。 将溶液酸化以允许分离巴柳氮,e。 任选地将巴柳氮转化为药学上可接受的盐(例如二钠盐)。
    • 7. 发明申请
    • Process For The Preparation Of (S)-Alpha-Ethyl-2-Oxo-1-Pyrrolidineacetamide And (R)-
Alpha-Ethyl-2-Oxo-Pyrrolidineacetamide
    • 制备(S)-α-乙基-2-氧代-1-吡咯烷乙酰胺和(R) -
    • US20090069575A1
    • 2009-03-12
    • US11667824
    • 2005-11-21
    • Yuan Qiang LiZhi-Xian WangBhaskar Reddy Guntoori
    • Yuan Qiang LiZhi-Xian WangBhaskar Reddy Guntoori
    • C07D207/12
    • C07D207/27
    • A process provided for the preparation of the (S)— and (R)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide of formula:(1) from (RS)-alpha-ethyl-2-oxo-1-pyrrolidineacetic acid of formula:(2) comprising: i) combining the (RS)-2 with a chiral base (resolving agent) in a resolution solvent and crystallizing from the said mixture the diastereomeric salt of (S)— or (R)-2 and chiral base; ii) regenerating (S)— or (R)-2 from the crystallized diastereomeric salt by treating with a suitable acid or acidic ion-exchange resin; iii) optionally regenerating (R)— or (S)-2 or their mixture (predominantly one enantiomer) from the crystallization mother liquor by treating with a suitable acid or acidic ion-exchange resin; iv) optionally epimerizing (RS)-2 by treating (R)— or (S)-2 or their mixture (predominantly one enantiomer) of step iii with an acid anhydride; V) optionally converting (RS)-2 of step iv into enantiomerically enriched (S)— or (R)-2 through steps i and ii; vi) formation of the mixed anhydride by reacting (R)— or (S)-2 with an alkyl or aryl sulfonyl halogen compound RSO2X in the presence of a suitable base; and vii) reacting the mixed anhydride with ammonia; wherein R represents C 1 to C 15 alkyl or aryl groups such as methyl, ethyl, p-toluenyl, 2,4,6-trimethylbenzyl, 2,4,6-trichloribenzyl, and X represents a halogen atom such as F, Cl and Br atoms.
    • (RS)-α-乙基-2-氧代-1-吡咯烷乙酸的(S) - 和(R)-α-乙基-2-氧代-1-吡咯烷乙酰胺的制备方法 式(2)的酸包括:i)将(RS)-2与分解溶剂中的手性碱(拆分剂)组合并从所述混合物中结晶出(S) - 或(R)-2的非对映体盐 和手性基; ii)通过用合适的酸或酸性离子交换树脂处理从结晶的非对映体盐再生(S) - 或(R)-2) iii)通过用合适的酸或酸性离子交换树脂处理任选地从结晶母液中再生(R) - 或(S)-2或它们的混合物(主要是一种对映异构体) iv)通过用酸酐处理(R) - 或(S)-2或它们的步骤iii的混合物(主要是一个对映异构体)任选差向异构化(RS)-2; V)任选地通过步骤i和ii将步骤iv的(RS)-2转化成对映异构体富集的(S) - 或(R) vi)通过使(R) - 或(S)-2与烷基或芳基磺酰基卤化合物RSO 2 X在合适的碱的存在下反应形成混合酸酐; 和vii)使混合酸酐与氨反应; 其中R表示C 1至C 15烷基或芳基如甲基,乙基,对甲苯基,2,4,6-三甲基苄基,2,4,6-三氯苄基,X表示卤素原子如F,Cl和 Br原子。
    • 9. 发明申请
    • Process for the preparation of atorvastatin and intermediates
    • 制备阿托伐他汀和中间体的方法
    • US20090131683A1
    • 2009-05-21
    • US12222690
    • 2008-08-14
    • Fan WangDaqing CheBhaskar Reddy GuntooriYajun ZhaoAaron C. KinsmanJody FaughtAlan Chow
    • Fan WangDaqing CheBhaskar Reddy GuntooriYajun ZhaoAaron C. KinsmanJody FaughtAlan Chow
    • C07D207/333
    • C07D207/34
    • A process is provided for preparing (R)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-5-hydroxy-3-oxo-1-heptanoic acid, R-substituted ester 9 comprising: (a) reacting the aldehyde 1 with the enolate form of (S)-2-hydroxy-1,2,2-triphenylethyl acetate substituent in a chelating co-solvent; (b) hydrolysis of (R,S)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-3-hydroxy-1-pentanoic acid, (S)-2-hydroxy-1,2,2-triphenylethyl ester (2a and 2b) using a base, preferably an alkali metal base, preferably in a solvent to form the carboxylic acid 7; (c) treating the acid 7 with a chiral base to form a salt and purifying the salt to obtain enantiomerically enriched (R)-7 chiral base salt; (d) alkylation of the (R)-7 chiral base salt or the free base derived from (R)-7, forming (R)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-5-hydroxy-3-oxo-1-heptanoic acid, R-substituted ester 9 and atorvastatin calcium 6, wherein R is a C1 to C6 alkyl, C6 to C9 aryl or C7 to C10 aralkyl.
    • 提供了制备(R)-5- [2-(4-氟苯基)-5-(1-甲基乙基)-3-苯基-4 - [(苯基氨基)羰基] -1H-吡咯-1-基] -5-羟基-3-氧代-1-庚酸,R-取代的酯9,其包含:(a)使醛1与烯醇化形式的(S)-2-羟基-1,2,2-三苯基乙基乙酸酯取代基 在螯合助溶剂中; (b)(R,S)-5- [2-(4-氟苯基)-5-(1-甲基乙基)-3-苯基-4 - [(苯基氨基)羰基] -1H-吡咯-1-基 ] -3-羟基-1-戊酸,(S)-2-羟基-1,2,2-三苯基乙酯(2a和2b),使用碱,优选碱金属碱,优选在溶剂中形成羧酸 酸7; (c)用手性碱处理酸7以形成盐并纯化该盐以获得对映体富集的(R)-7手性碱盐; (d)(R)-7手性碱盐或衍生自(R)-7的游离碱的烷基化,形成(R)-5- [2-(4-氟苯基)-5-(1-甲基乙基) - 3-苯基-4 - [(苯基氨基)羰基] -1H-吡咯-1-基] -5-羟基-3-氧代-1-庚酸,R-取代的酯9和阿托伐他汀钙6,其中R是C1 C6烷基,C6〜C9芳基或C7〜C10芳烷基。